There is no excerpt because this is a protected post.
We track the Biotech iShares each week, and here is the up to the minute view of a constructive situation breaking to a bullish one.
As everybody knows, long-term interest rates have been rising since the beginning of September, well before the FOMC supposedly surprised markets with a lean to
Here is one of the inter-market views that I find interesting. The Biotech iShares is constructive vs. the QQQ on a daily chart as the
As you surely know, they don’t all work this way. But trading GILD has been like clockwork for me since buying the lows in June.
It’s been a great run off the June bottom and now all Biotech profits are booked. I’ll hold general Healthcare for now, with all individual
There was the high, tight one on Biotech iShares, IBB and then others noted on the Medical Device iShares, IHI and the general sector SPDR,
The Biotech iShares IBB shot up on some beneficial talk out of the Trump administration and, in my opinion, on beneficial Treasury yield dynamics. So
We have used this chart in NFTRH to gauge the state of the ongoing secular bull market in Biotech vs. other Tech. The series of
As to the post’s title, I have no idea. What I do know is that a nice profit is in the books on a suddenly
Yesterday we got the surge and then the ease into the close. Today? Err… The weekly now targets 350, barring a harsh reversal over the
It’s been a long time coming for the Biotech sector that has for me included some stops and starts in AMGN, GILD and IBB itself.
While I currently work with all sorts of macro-fundamental indicators and inter-market ratio charts, I started out just loving the act of creating and analyzing
First off, I believe we are entering a rising interest rate environment, quite possibly in line with the preferred view of inflationary pressures out ahead.